Field Trip Health Ltd

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ:FTRP), a company in the psychedelics space, which is developing a chain of psychedelics-assisted therapy clinics throughout North America and Europe. The firm gave Field Trip a Buy rating and a $20 price target, pushing the company's shares from $4.5 on Tuesday at market close to $5.3 on Wednesday morning.

Field Trip Stock Could Climb 300% In One Year

Field Trip Health (NSADAQ: FTRP) shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target. The firm said it finds the company's valuation 'compelling' ahead of the anticipated Phase 1 top-line data on FT-104, saying it could be a 'disruptive psilocybin-like treatment.

Why Field Trip Health Shares Are Trading Higher Today

TORONTO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce the launch of “KAP Co-op”, a program that enables eligible independent psychedelic therapists to provide ketamine-assisted psychotherapy (and, in the future, other legal, psychedelic-assisted therapies) at its Field Trip Health centers. Field Trip is also pleased to announce the launch of training programs designed to provide interested psychotherapists or other qualified mental health professionals and clinicians with access to best-in-class training on KAP.

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians

TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

TORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its first fiscal quarter ended June 30, 2021, after market close on Monday, August 16, 2021.

Field Trip Health Ltd. Schedules First Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, August 17, 2021 at 8:30 am ET

News for Field Trip Health Ltd Stock (FTRP)